Joel Latham on a Promising New Combination Therapy for Obstructive Sleep Apnea

Recently, Incannex Healthcare announced that patient dosing has commenced in their phase 2/3 RePOSA clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). OSA is significantly undertreated. There are currently no US Food and Drug Administration-approved medications for OSA, and patient compliance to positive airway pressure devices is low. Earlier studies demonstrated that IHL-42X reduced the apnea hypopnea index, the standard measure of OSA, by an average of greater than 50% at the low dose, and 25% of those patients had an 80% reduction.

DocWire News spoke with Joel Latham, president and CEO of Incannex, to find out more about the company’s proprietary fixed-dose combination drug and how it will positively impact patients with OSA.